Soft tissue sarcomas (STS) are heterogeneous, mesenchymal malignancies with variable biologic behavior. The primary management for localized STS is surgical resection, which may be combined with neoadjuvant or adjuvant radiation therapy to increase the probability of achieving local control. Many patients with large, high-grade STS develop metastatic disease. Several clinical trials of immune checkpoint blockade for STS have produced promising responses in patients with metastatic disease. In this review, recent and ongoing clinical trials of immune checkpoint inhibition for STS are discussed. The authors explain the rationale for immune checkpoint inhibition and radiation therapy and highlight new studies testing this combination in the neoadjuvant setting for patients with high-risk STS. In addition, they describe novel combinations of immunotherapy with targeted therapies and chemotherapies being tested in the metastatic setting and discuss how these combinations have the potential to be integrated into adjuvant therapy in the future.
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The primary management for localized STS is surgical resection. For patients with large and/or high-grade STS, neoadjuvant or adjuvant radiation therapy often is used to improve local control. [7] [8] [9] For many STS subtypes, the value of adjuvant chemotherapy remains controversial. [10] [11] [12] After local treatment, approximately 50% of patients with large, highgrade sarcomas develop metastases, which most commonly occur the lung. 13 After metastases occur, available systemic therapies can temporarily decrease disease burden, but median survival remains less than 2 years. 14, 15 Alternative approaches are needed to reduce the number of patients with sarcoma who develop metastases and thus improve survival.
Sarcoma has a rich history of immuno-oncology research. In 1891, Dr. William Coley, now known as the "Father of Immunotherapy," first demonstrated the ability of the immune system to reject a malignant tumor in a patient with sarcoma. 16 Dr. Coley injected tumors with a live preparation of streptococcus organisms designated as "Coley's toxins," which caused the infection erysipelas and presumably stimulated the immune system. 16 Over his long career, he treated hundreds of patients who had inoperable and metastatic sarcomas using immunotherapy, which reportedly had remarkable results. 16 With the development of radiation and chemotherapy, "Coley's toxins" fell out of favor and, for many years, immunotherapy was not used to treat patients with sarcoma. The reemergence of immunotherapy in the context of immune checkpoint blockade has led to the development of clinical trials testing these immunomodulatory agents for the treatment of STS.
IMMUNE CHECKPOINT INHIBITION
The use of immune checkpoint inhibition has become a major focus in oncology because of the dramatic and durable responses reported in patients with multiple tumor types. [17] [18] [19] The goal of immunotherapy is to stimulate the immune system to attack malignant tumor cells. 20 Immune checkpoint inhibitors rely on the activation of a patient's existing antitumor immune cells. 20, 21 The best response rates have been observed in patients with lung cancer and melanoma, which often are highly mutated tumors and thus express numerous tumor-specific neoantigens against which the immune system may mount an attack. 17, 22, 23 Because of the impressive results of immune checkpoint blockade in many cancers, several clinical trials are now testing immune checkpoint inhibitors in STS.
Immune checkpoint blockade is a powerful approach to activating antitumor immunity. Immune checkpoints are inhibitory pathways that modulate the duration and magnitude of immune responses and preserve self-tolerance. 20 A major mechanism by which cancers evade the immune system is by exploiting these immune checkpoint pathways 24 to prevent T cells from recognizing tumor-specific antigens and eliminating tumor cells. 25, 26 Because many immune checkpoint signaling cascades are initiated by ligand-receptor interactions on the cell surface, 20 they can be blocked by antibodies. These antibodies can "release the brakes" on the immune system, which has the potential to unleash an antitumor immune response. The major targets of US Food and Drug Administration-approved immunotherapeutic antibodies are programmed death protein-1 (PD-1), its ligand programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Although inhibitory anti-CTLA-4 and anti-PD-1 antibodies have been used to successfully treat many cancers, they remain relatively understudied in STS. Here, we review the current landscape of immune checkpoint inhibitor trials in STS and discuss opportunities for incorporating immunotherapy into the neoadjuvant and adjuvant settings.
IMMUNOLOGIC PROFILE OF STS
In a recent study, Pollack and colleagues characterized the immunologic profile of 5 common STS subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma, and liposarcoma (both well differentiated/dedifferentiated liposarcoma and myxoid/ round cell liposarcoma subtypes). 27 They observed that UPS and leiomyosarcoma, 2 of the more genetically "complex" sarcomas, had high gene expression levels related to antigen presentation and T-cell infiltration as well as a more oligoclonal T-cell receptor repertoire. Compared with other sarcoma subtypes, UPS also had the most T-cell infiltration and the highest expression of PD-1 and PD-L1 (Fig. 1) . Prior receipt of radiotherapy or chemotherapy was not associated with T-cell infiltration or clonality. Another study examining tumor immunecell infiltrate in 17 patients with UPS demonstrated increased T cells after neoadjuvant radiotherapy (50 grays [Gy] in 25 fractions). 28 The median CD4 infiltrate increased significantly (from 3 to 13 cells/mm 2 ; P 5 .01), and a similar trend was observed for CD8 infiltrate (from 55 to 111 cells/mm 2 ; P 5 .17). The immune cell infiltrates did not differ significantly between patients who received neoadjuvant radiotherapy alone versus those who received neoadjuvant chemotherapy and radiotherapy. Although no PD-L1 expression was observed at baseline, 21% of tumors exhibited PD-L1 staining after radiotherapy.
Recently, The Cancer Genome Atlas Research Network reported the immune microenvironment signature of 206 STS across 7 histologic subtypes. 29 The immune microenvironment, which was determined from messenger RNA expression and DNA methylation profiles, revealed 3 distinct clusters. It is noteworthy that the 3 sarcoma subtypes that had high levels of copy number alterations (UPS, myxofibrosarcomas [MFS] , and dedifferentiated liposarcomas) had similar immune microenvironments; and, in UPS and MFS, the presence of dendritic cells was correlated with improved disease-specific survival, suggesting a role for antigen presentation in the response of the immune system to these sarcomas. 29 Taken together, these studies suggest that STS, especially those with a high frequency of copy number alterations (such as UPS and MFS), 27 ,29 may be capable of eliciting an immune response. Therefore, some histologic STS subtypes may be poised to respond to immune checkpoint inhibitors or other immunotherapies. However, the optimal treatment approach will likely be subtypespecific. Further work is necessary to understand differences in immune response for each sarcoma subtype and how current treatments, such as radiotherapy and chemotherapy, affect this response.
RADIATION AND IMMUNOTHERAPY
As the use of immune checkpoint blockade increased in patients with non-small cell lung cancer and melanoma, [17] [18] [19] abscopal effect case reports began to appear in the literature. [30] [31] [32] [33] The abscopal effect, 30 in which local irradiation elicits a systemic immune response leading to regression of distant tumors outside of the radiation field, provides rationale for combining immune checkpoint blockade and radiation therapy (Fig. 2) . In preclinical studies, abscopal responses after radiotherapy and immune checkpoint blockade have been reliably reproduced in transplanted tumor models in immunocompetent mice, 34, 35 but this phenomenon remains relatively uncommon in clinical practice. 30 Numerous ongoing preclinical studies and active clinical trials seek to determine the optimal radiotherapy fractionation and timing relative to immune checkpoint blockade to activate an abscopal response. Although radiation has historically been considered a treatment focused on achieving local tumor control, mounting evidence suggests that radiation alone can elicit an immune response 36 ; therefore, radiation has the potential to synergize with immune checkpoint blockade to produce a durable antitumor response not only within the radiation field but also against distant metastatic disease. 33, 37 The potential impact of an abscopal response is high in STS, in which approximately 50% of patients who have large, high-grade tumors develop metastases. 13 The frequent development of metastases despite local tumor control suggests that micrometastatic disease is often present at the time of primary tumor resection. Combining Figure 2 . Abscopal response may eliminate micrometastatic disease in patients with soft tissue sarcoma. In an abscopal response, the primary tumor (green) is treated with radiation therapy, which has demonstrated the ability to generate a systemic immune response. The antitumor immune response is mediated by both CD4 and CD8 T cells (yellow). This response may be further enhanced by blocking the inhibitory checkpoints cytotoxic T-lymphocyte-associated antigen-4 (orange) and/or programmed cell death protein-1 (purple) on the surface of CD4 and CD8 T cells. By increasing activation and effector function of T cells, immune checkpoint blockade has the potential to eradicate both irradiated and nonirradiated tumor cells. This has the potential to dramatically improve outcomes for patients with soft tissue sarcoma by eradicating micrometastatic disease.
immunotherapy and neoadjuvant radiotherapy has the potential to elicit a systemic immune response to improve long-term survival in patients with sarcoma by eradicating micrometastatic disease. In the 1970s, Dr. Helen Stone and her colleagues used a mouse model of sarcoma to demonstrate that the immune system plays an important role in tumor response to radiation therapy. 38 In an allograft STS model, they demonstrated that a higher radiation dose was needed to achieve tumor cure in immunodeficient mice compared with immunocompetent mice, suggesting that the immune system contributes to tumor elimination after radiation therapy. 38 Most clinical trials testing the combination of radiation and immunotherapy are in the setting of established metastatic disease. 39 However, lower pretreatment tumor volume has been correlated with improved response to immune checkpoint blockade, 40 suggesting that combining radiation therapy and immunotherapy may be more effective in the definitive setting. For example, adjuvant treatment with the anti-PD-L1 antibody durvalumab after definitive chemoradiation for stage III non-small cell lung cancer significantly improved progression-free survival compared with chemoradiation followed by placebo. 18 Neoadjuvant and/or adjuvant immune checkpoint blockade would be a paradigm shift for the management of tumors with a high risk for developing metastases, such as STS-using immunotherapy to prevent, rather than to treat, metastatic disease.
Although preclinical studies and anecdotal clinical outcomes testing the combination of radiation and immunotherapy have generated significant excitement, to our knowledge, no mature randomized clinical trials in treatment-naive patients have established the superiority of radiation therapy and concurrent immunotherapy over either radiotherapy alone or immunotherapy alone. In many ongoing trials, patients receive treatment with combined checkpoint blockade and radiation therapy after they have progressed through chemotherapy or immune checkpoint blockade alone. 39 However, this design makes it challenging to determine whether there is synergy from the combination of immune checkpoint blockade and radiation therapy. Even for patients who progress on immune checkpoint blockade alone but subsequently respond to the same immunotherapy combined with radiotherapy, the response cannot necessarily be attributed to radiotherapy given the potential for delayed responses to immune checkpoint inhibition. 41 44 Although synovial sarcoma is a translocation-driven sarcoma with relatively low mutational burden, 45 it often has high expression of the endogenous cancer testis antigen NY-ESO-1. 46, 47 Six patients with synovial sarcoma received 3 doses of ipilimumab in the study by Maki and colleagues 44 ; of these, only 4 patients completed treatment, and all patients exhibited radiologic evidence of disease progression by the third cycle. Emerging data in STS characterizing T-cell infiltration and immune checkpoint molecules, such as PD-1 and PD-L1, suggest that the more genetically "complex" histologic subtypes, such as UPS and leiomyosarcoma, 27 may be more likely to respond to immune checkpoint inhibitors.
Uterine leiomyosarcoma has also demonstrated resistance to immune checkpoint inhibition. In a phase 2 study of 12 patients who had previously treated, advanced uterine leiomyosarcoma (NCT02428192), no patients responded to the anti-PD-1 antibody nivolumab, as measured by progression-free survival (PFS). 48 By contrast, 1 report describes a treatment-naive patient with metastatic uterine leiomyosarcoma who experienced an impressive response to the anti-PD-1 antibody pembrolizumab. 49 After 9 months of pembrolizumab, all lesions exhibited significant regression except for a single mass, which was resected. After resection, the patient has experienced >2 years of complete tumor remission. Intriguingly, the treatment-resistant lesion harbored biallelic phosphatase and tensin homolog (PTEN) loss and decreased expression of 2 neoantigens expressed in the primary tumor, 49 which suggest potential mechanisms of resistance to PD-1 blockade.
Early results from an ongoing study examining combined anti-PD-L1 and anti-CTLA-4 immune checkpoint blockade for metastatic sarcoma (NCT02815995) demonstrate activity in some histologic subtypes. In that phase 2, multiarm study, patients with previously treated STS or bone sarcoma received anti-PD-L1 (durvalumab) and anti-CTLA-4 (tremelimumab) therapy for 4 cycles, followed by durvalumab for 12 weeks. According to Immune-Related Response Criteria (irRC), 1 of 4 patients with metastatic UPS had a partial response to combined immune checkpoint inhibition. Another clinical trial testing anti-PD-1 therapy in sarcomas is SARC028 (NCT02301039), which is a phase 2 trial of pembrolizumab in 86 patients with unresectable, metastatic, or recurrent STS or bone sarcoma. The primary outcome measure of the study is the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1); and secondary endpoints are adverse events, PFS, overall survival (OS), and response rates by irRC. For the initial cohort, 7 of 40 patients with STS had an objective response, with promising response rates for specific histologic subtypes. In particular, 1 complete response and 3 partial responses were observed among 10 patients who had UPS, and 2 partial responses were observed among 10 patients who had dedifferentiated liposarcoma. 51 Response rates were 1 of 10 and 0 of 10 for synovial sarcoma and leiomyosarcoma, respectively. Patients who responded to pembrolizumab had higher tumorinfiltrating lymphocytes at baseline. 52 The median PFS was 18 weeks among the 40 evaluable patients who had STS. For patients who had UPS or dedifferentiated liposarcoma, the median PFS was 30 weeks and 25 weeks, respectively. The median OS was 49 weeks among all patients with STS, but the median OS had not been reached for patients with UPS. 51 Enrollment on SARC028 was recently expanded for the UPS and dedifferentiated liposarcoma cohorts.
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The Alliance for Clinical Trials in Oncology conducted a randomized phase 2 trial (Alliance A091401; NCT02500797) of immune checkpoint blockade in patients who had metastatic or unresectable bone sarcoma or STS with progressive disease after alternative regimens. 53 Patients received either nivolumab alone or nivolumab in combination with ipilimumab. The primary endpoint was the tumor ORR (confirmed complete or partial response lasting at least 4 weeks). Secondary outcome measures included adverse events, the clinical benefit rate, response duration, PFS, and OS. Included histologies among the first 85 patients were as follows: 4% angiosarcoma, 34% leiomyosarcoma, 6% liposarcoma, 13% UPS, 13% spindle cell sarcoma, 5% synovial sarcoma, 10% bone sarcoma, and 15% other. Interim results revealed a low response with nivolumab monotherapy (5% ORR), with partial responses observed in patients who had alveolar soft part sarcoma, leiomyosarcoma, and sarcoma not otherwise specified. Combined nivolumab and ipilimumab appeared to have better antitumor activity (16% ORR), with complete responses observed in 1 patient who had myxofibrosarcoma and 1 patient who had uterine leiomyosarcoma. Partial responses to nivolumab and ipilimumab were observed in 2 patients who had UPS, 1 patient who had uterine leiomyosarcoma, 1 patient who had nonuterine leiomyosarcoma, 1 patient who had myxofibrosarcoma, and 1 patient who had angiosarcoma. The median PFS was 1.7 months for those who received nivolumab alone and 4.1 months for those who received combined nivolumab and ipilimumab. Enrollment is closed, although the study is ongoing.
No trials to date have compared immune checkpoint therapy with anthracyclines, which are standard first-line chemotherapy for many subtypes of metastatic sarcoma. MEDISARC is a German phase 2 clinical trial (NCT03317457) that randomizes patients who have metastatic or locally advanced sarcoma to receive durvalumab and tremelimumab versus 6 cycles of doxorubicin. Eligible histologic subtypes include fibrosarcoma, UPS, leiomyosarcoma, liposarcoma (dedifferentiated, pleomorphic, or myxoid), malignant glomus tumor, rhabdomyosarcoma (alveolar or pleomorphic), angiosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors. The primary outcome is OS, with secondary endpoints including adverse events, ORR, PFS, duration of response, and quality of life. Estimated enrollment is 100 patients, and the study recently opened in December 2017.
COMBINATIONS OF TARGETED THERAPY OR CHEMOTHERAPY WITH IMMUNE CHECKPOINT BLOCKADE
Novel combinations of immunotherapy with targeted therapies and chemotherapies in STS have been tested primarily in the metastatic setting. 54 If regimens that are active against metastatic disease are identified, then they have the potential to be tested as adjuvant therapy in the future. One early, retrospective study of 28 patients who had relapsed, metastatic or unresectable STS or bone sarcoma examined the safety and efficacy of nivolumab. 55 Many patients, including some responders, were concurrently receiving pazopanib, a multikinase inhibitor that was approved for sarcoma in 2012. 56 Response was assessed using RECIST 1.1 criteria by comparing baseline imaging with positron emission tomography/computed tomography images obtained after at least 4 doses of nivolumab. Three partial responses were observed, each in 1 patient with dedifferentiated chondrosarcoma, epithelioid sarcoma, and maxillary osteosarcoma. Nine patients had stable disease, including 3 patients with leiomyosarcoma. This retrospective study suggested clinical benefit (partial response or stable disease) in 50% of patients with sarcoma after >4 cycles of nivolumab. The most common severe adverse events (grade 3-4) were liver function test elevation, colitis, and pneumonitis; and all 5 severe adverse events occurred in patients who had received treatment with concomitant pazopanib.
A recent phase IB study (NCT01643278) examined the safety and efficacy of the tyrosine kinase inhibitor dasatinib combined with ipilimumab in 20 patients who had gastrointestinal stromal tumors and 8 patients who had other sarcoma subtypes. 57 Patients received a 1-week dasatinib lead-in, then 3 or 10 mg/kg ipilimumab every 3 weeks with dasatinib, followed by maintenance dasatinib (70 mg daily, 100 mg daily, or 70 mg twice daily). Although this regimen was well tolerated, efficacy was poor. Eighteen patients were evaluable for radiographic response, and no partial or complete responses were observed based on RECIST 1.1 or irRC.
Results recently were reported from a French multicenter, phase 2 clinical trial (NCT02406781) assessing pembrolizumab with metronomic cyclophosphamide in patients with metastatic STS, including leiomyosarcoma, UPS, gastrointestinal stromal tumors, and several other histologies. 58 Although treatment was well tolerated, responses were limited, with 3 of 50 patients free from progression at 6 months. The median PFS was 1.4 months across all histologies. Tumor sample evaluation revealed high expression levels of indoleamine 2,3-dioxygenase 1 (IDO1) in infiltrating immune cells, and the kynurenine-to-tryptophan ratio in plasma increased significantly after pembrolizumab. Given the role for the IDO1 product kynurenine in regulatory T-cell expansion, the authors posit that the IDO1 pathway may be contributing to pembrolizumab resistance, providing rationale for combining anti-PD-1 therapy with IDO1 inhibitors for STS.
Multiple dose-escalation studies are ongoing to test the combination of chemotherapy and dual anti-CTLA-4 and anti-PD-1 immune checkpoint blockade in STS. The Sarcoma Oncology Research Center is conducting an open-label, phase 1/2 trial (NCT03138161) testing trabectedin, ipilimumab, and nivolumab in patients with STS. 59 In phase 1, previously treated patients will receive ipilimumab, nivolumab, and escalating doses of trabectedin (1.0 mg/m 2 , 1.2 mg/m 2 , then 1.5 mg/m 2 ; 3-6 patients per dose) to identify the maximum tolerated dose (MTD). After dose escalation, [22] [23] [24] [25] [26] [27] [28] previously untreated patients will receive trabectedin at the MTD in combination with ipilimumab and nivolumab, with possible surgical resection after the first treatment cycle. The primary outcome measure is the trabectedin MTD, and the secondary outcome measures are the ORR at 24 months, 6-month PFS, and 6-month OS.
An ongoing phase 1/2 trial at the University of Washington (NCT02888665) is assessing the safety and efficacy of pembrolizumab with doxorubicin for patients with metastatic or unresectable sarcoma. Patients receive pembrolizumab every 3 weeks with concurrent doxorubicin for cycles 2 through 7. The primary outcomes are the doxorubicin MTD and ORR compared with historic control rates. Secondary outcomes include response duration, incidence of adverse events, PFS, OS, and time to response. Completed data collection for primary outcome measures is expected in August 2018.
The Royal Marsden National Health Service Foundation Trust is conducting an open-label trial (NCT03123276) of pembrolizumab and gemcitabine for leiomyosarcoma and UPS. 60 This is a 2-part, phase 1, single-center, dose-escalation, and dose-expansion study in 24 patients with newly diagnosed metastatic or inoperable leiomyosarcoma or UPS. The first 12 patients will be in the dose-escalation cohort: 6 patients will receive 800 mg/m 2 gemcitabine in combination with 200 mg pembrolizumab every 3 weeks. If no dose-limiting toxicities are noted, then gemcitabine will be increased to 1000 and 1200 mg/m 2 . The next 12 patients will be enrolled in the MTD cohort to study safety and tolerability and to preliminarily assess response to therapy. The primary endpoint is response evaluation according to RECIST 1.1 at 2 months after the last dose. Secondary outcome measures include immunophenotyping of tumor samples and response stratification according to tumor PD-L1 expression.
CLINICAL STUDIES OF NEOADJUVANT RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE IN STS
Although a subset of patients with metastatic, treatmentrefractory sarcoma respond to immune checkpoint blockade, it is conceivable that efficacy would be improved if it was administered to treatment-naive patients with less tumor burden. 40 The goal of neoadjuvant and/or adjuvant immunotherapy is to trigger immune clearance of clinically undetectable metastases. Decreased rates of metastasis would significantly improve outcomes for patients with STS. Neoadjuvant radiation therapy is often used to treat sarcoma and reportedly has contributed to an antitumor immune response with immune checkpoint blockade in many preclinical and clinical studies with various tumor types. 34, 37, 61, 62 63 The study will evaluate the safety, tolerability, and efficacy of durvalumab and tremelimumab in combination with radiation before surgical resection of high-risk STS. Patients who have no evidence of disease after surgery will receive 4 additional doses of durvalumab, and those who have evidence of residual disease after surgery will receive 9 additional doses of durvalumab unless there is clear disease progression. Patients with bulky sarcomas (>10 cm) also will receive a single 15-Gy fraction of high-dose spatially fractionated (GRID) radiation therapy 1 to 3 days before standard fractionated radiation therapy. The endpoints are histopathologic response in the surgical resection specimen and the number of patients experiencing highgrade toxicity. Secondary outcome measures include OS, the disease-specific survival rate, the relapse-free survival rate, and radiologic response to treatment (RECIST 1.1 and irRC). NEXIS opened in June 2017, and the estimated completion date is June 2022.
The University of Texas MD Anderson Cancer Center recently opened a randomized phase 2 clinical trial (NCT03307616) to compare neoadjuvant nivolumab alone versus neoadjuvant nivolumab plus ipilimumab in patients with surgically resectable UPS or retroperitoneal dedifferentiated liposarcoma. Patients with UPS of the trunk or extremities receive concurrent radiation therapy starting 2 weeks after the first cycle of nivolumab with or without ipilimumab. The primary endpoint is pathologic response measured as the percentage hyalinization in the surgical resection specimen. Secondary measures include immunologic response, change in immune infiltrate relative to baseline, ORR, recurrence-free survival, OS, and safety. The study opened in October 2017, and estimated enrollment is 40 patients.
SU2C-SARC032 (NCT03092323) is an ongoing, multicenter, randomized clinical trial to examine the safety and efficacy of neoadjuvant pembrolizumab and radiation therapy in patients with clinically localized, high-risk STS of the extremity. This trial tests whether the addition of neoadjuvant PD-1 immune checkpoint blockade with pembrolizumab to radiation therapy and adjuvant pembrolizumab can activate a systemic antitumor response to eliminate micrometastatic disease and improve disease-free survival. SU2C-SARC032 opened in July 2017 with a planned accrual of 110 patients.
On the basis of promising results from SARC028 in specific sarcoma subtypes, enrollment for SU2C-SARC032 is restricted to patients who have UPS or dedifferentiated/pleomorphic liposarcoma. Patients are randomized to receive neoadjuvant radiation therapy (50 Gy in 25 fractions) followed by surgical resection (standard of care) versus neoadjuvant radiotherapy with 3 cycles of concurrent pembrolizumab (once before, during, and after radiotherapy) followed by surgical resection and adjuvant pembrolizumab. In the experimental arm, patients receive up to 1 year of pembrolizumab (3 cycles of neoadjuvant and 14 cycles of adjuvant pembrolizumab). The primary endpoint is 2-year disease-free survival. Secondary endpoints include toxicity, local control, metastasis-free survival, and OS. Correlative studies from NEXIS, the MD Anderson trial, and SU2C-SARC032 may improve the understanding of immune checkpoint inhibition and radiotherapy in STS, inform patient selection for future clinical trials, and potentially identify novel targets for immunotherapy of STS.
CONCLUSIONS
Preclinical evidence suggests a role for the immune system in the therapeutic response of sarcomas, but clinical data remain limited. The need for hypothesis-driven clinical trials is clear, and ongoing phase 2 trials are examining immune checkpoint blockade, either alone or in combination chemotherapy or radiation therapy, for patients who have high-risk, localized disease. If successful, immune checkpoint inhibition could represent a paradigm shift for immunotherapy in the treatment of sarcoma, from treating established metastases to preventing the development of metastatic disease (Fig. 2) . Correlative studies will be essential to inform patient selection for future trials and to optimize this therapeutic approach. Much remains to be learned from these ongoing trials, which have the potential to change the way we treat patients with STS. 
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